| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC | Director | Common Stock | 50.3K | $1.54M | $30.52 | Feb 10, 2025 | Direct |
| Akebia Therapeutics, Inc. | Director | Common Stock | 48.6K | $59.4K | $1.22 | Jun 2, 2021 | Direct |
| enGene Holdings Inc. | Director | Stock Option (Right to Buy) | 45K | Jul 8, 2025 | Direct | ||
| Trevi Therapeutics, Inc. | Director | Nonstatutory Stock Option (right to buy) | 45K | Jun 11, 2025 | Direct | ||
| Biohaven Ltd. | Director | Stock Options (Right to buy) | 31.7K | May 5, 2025 | Direct | ||
| SYNLOGIC, INC. | Director | Stock Option (right to buy) | 30K | Jun 22, 2023 | Direct | ||
| Avalo Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 29.5K | Jun 17, 2025 | Direct | ||
| Akebia Therapeutics, Inc. | Director | Stock Option (Right to buy) | 20.1K | Jun 2, 2021 | Direct | ||
| Biohaven Pharmaceutical Holding Co Ltd. | Director | Restricted Share Unit Award | 0 | Oct 3, 2022 | Direct | ||
| Biohaven Pharmaceutical Holding Co Ltd. | Director | Stock Options (Right to Buy) | 0 | Oct 3, 2022 | Direct |